BridgeBio Pharma Pre-Tax Profit Margin 2018-2026 | BBIO
Current and historical pre-tax profit margin for BridgeBio Pharma (BBIO) from 2018 to 2026. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. BridgeBio Pharma pre-tax profit margin for the three months ending March 31, 2026 was .
| BridgeBio Pharma Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2026-03-31 | $0.58B | $-0.73B | -125.65% |
| 2025-12-31 | $0.50B | $-0.73B | -145.73% |
| 2025-09-30 | $0.36B | $-0.80B | -226.48% |
| 2025-06-30 | $0.24B | $-0.78B | -329.96% |
| 2025-03-31 | $0.13B | $-0.68B | -528.13% |
| 2024-12-31 | $0.22B | $-0.54B | -244.14% |
| 2024-09-30 | $0.22B | $-0.45B | -204.59% |
| 2024-06-30 | $0.22B | $-0.46B | -210.50% |
| 2024-03-31 | $0.22B | $-0.55B | -249.32% |
| 2023-12-31 | $0.01B | $-0.65B | -6530.00% |
| 2023-09-30 | $0.01B | $-0.62B | -6240.00% |
| 2023-06-30 | $0.01B | $-0.59B | -9750.00% |
| 2023-03-31 | $0.08B | $-0.43B | -547.44% |
| 2022-12-31 | $0.08B | $-0.49B | -621.79% |
| 2022-09-30 | $0.09B | $-0.50B | -557.30% |
| 2022-06-30 | $0.09B | $-0.52B | -568.13% |
| 2022-03-31 | $0.07B | $-0.62B | -867.61% |
| 2021-12-31 | $0.07B | $-0.59B | -849.28% |
| 2021-09-30 | $0.06B | $-0.57B | -1016.07% |
| 2021-06-30 | $0.06B | $-0.54B | -867.74% |
| 2020-09-30 | $0.02B | $-0.45B | -2063.64% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |